Publication: İnsan immünyetmezlik virus-1 (HIV-1) pozitif bireylerde integraz gen mutasyonlarının araştırılması
Abstract
Amaç: İnsan İmmünyetmezlik Virusu/ Edinilmiş İmmünyetmezlik Sendromu (HIV/ AIDS) tüm dünyayı ilgilendiren en önde gelen sağlık sorunlarından birisidir. HIV enfeksiyonunun tedavisi için çeşitli antiretroviral ajanlar kullanılmaktadır. İntegraz inhibitörleri yüksek derecede aktif antiretroviral tedavi (HAART) rejiminde kullanıma giren en son ilaç sınıfıdır. Ülkemizde 2017 yılı itibariyle integraz inhibitörleri de HIV tedavisinde kullanıma girmiştir. Tedavide yeni kullanıma girmesi sebebiyle, integraz inhibitörlerine karşı gelişen antiviral direnci saptama çalışmaları henüz rutin olarak yapılmamaktadır. Bu nedenle HIV pozitif hastalarda integraz inhibitörleri direnç paternlerinin tespit edilmesi hastalığın prognozu için önem teşkil etmektedir. Bu çalışmada, 2018-2019 döneminde T.C.S.B. Marmara Üniversitesi Pendik Eğitim Araştırma Hastanesi'nde mikrobiyoloji tetkikleri için laboratuvara gelen ve HIV-1 pozitif olduğu tespit edilen plazma örnekleri ile çalışılmıştır. Amacımız klinik HIV-1 izolatlarında integraz gen mutasyonlarını araştırmaktır. Gereç ve Yöntem: -80oC'de saklanan plazma örneklerinden viral RNA ekstraksiyonu yapıldıkta sonra PCR için cDNA sentezi yapıldı. İntegraz bölgesine spesifik primerler kullanılarak PCR gerçekleştirildi ve ürünler Sanger dizileme ile dizilendi. Bulgular: Çalışılan 50 hasta serumunun 37 tanesinde integraz gen bölgesi çoğaltıldı ve 18 örneğin sekans analizi gerçekleştirildi. Sonuçlar: Sekans analizi yapılan 18 örneğin iki tanesinde integraz inhibitörlerine karşı dirence sebep olan mutasyon saptandı.
AIM: Human Immunodeficiency Virus/ Acquired Immuno Deficiency Syndrome (HIV/ AIDS) is still one of the most remarkable health challenges in the world. Various antiretroviral agents are used for the treatment of the HIV infection. Integrase inhibitor group is the newest drug class to be used in the HAART regimen. As of 2017, integrase inhibitors have been used in the treatment of HIV in our country. Because of its recent use in treatment, studies to detect antiviral resistance to integrase inhibitors are not routinely performed. Therefore, determination of resistance patterns to integrase inhibitors in HIV positive patients is important for the prognosis of the disease. In this study, plasma samples which were sent to the microbiology laboratory of T.C.S.B. Marmara University Pendik Training and Research Hospital in the period of 2014-2018 and found to be HIV-1 positive were studied. Our aim was to investigate integrase gene mutations in clinical HIV-1 isolates. Materials and Method: Viral RNA extraction was performed from plasma samples stored at -80oC and then cDNA synthesized. PCR was performed using primers specific for the integrase gene and the resulting products were sequenced by Sanger sequencing method. Results: The integrase gene region was amplified in 37 of the 50 patient sera studied and sequence analysis of 18 samples was revealed. Conclusion: Sequence analysis showed mutation causing resistance to integrase inhibitors in two of the 18 samples.
AIM: Human Immunodeficiency Virus/ Acquired Immuno Deficiency Syndrome (HIV/ AIDS) is still one of the most remarkable health challenges in the world. Various antiretroviral agents are used for the treatment of the HIV infection. Integrase inhibitor group is the newest drug class to be used in the HAART regimen. As of 2017, integrase inhibitors have been used in the treatment of HIV in our country. Because of its recent use in treatment, studies to detect antiviral resistance to integrase inhibitors are not routinely performed. Therefore, determination of resistance patterns to integrase inhibitors in HIV positive patients is important for the prognosis of the disease. In this study, plasma samples which were sent to the microbiology laboratory of T.C.S.B. Marmara University Pendik Training and Research Hospital in the period of 2014-2018 and found to be HIV-1 positive were studied. Our aim was to investigate integrase gene mutations in clinical HIV-1 isolates. Materials and Method: Viral RNA extraction was performed from plasma samples stored at -80oC and then cDNA synthesized. PCR was performed using primers specific for the integrase gene and the resulting products were sequenced by Sanger sequencing method. Results: The integrase gene region was amplified in 37 of the 50 patient sera studied and sequence analysis of 18 samples was revealed. Conclusion: Sequence analysis showed mutation causing resistance to integrase inhibitors in two of the 18 samples.